Therapy News and Research

RSS

CU Cancer Center test identifies key biomarkers in advanced lung cancer

Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical trial.

12 Oct 2011

British scientist wins NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation (NYSCF) announced today that a British stem cell scientist working to cure blindness will be the first recipient of The New York Stem Cell Foundation - Robertson Prize in Stem Cell Research, a $200,000 prize awarded annually for extraordinary achievement in translational stem cell research.

12 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

NIH, Genesis Biopharma enter Patent License Agreement for adoptive cell therapy

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

UCLA's screening system can target stem cells responsible for glioblastoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

12 Oct 2011

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function.

12 Oct 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

For men older than 50, a simple blood test to screen for prostate cancer is as much a part of annual physicals as weigh-ins and stethoscopes. The PSA test is painless, inexpensive and the only way to detect the disease - the most common male cancer - before symptoms turn up.

12 Oct 2011

Phyllodes tumors more prevalent among Hispanic women

According to a study published in the October issue of the Journal of the American College of Surgeons, phyllodes tumors - rare breast malignancies accounting for 0.5 to one percent of all breast tumors - tend to be more prevalent in Hispanic patients.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Antivirulence drugs may fight infection and suppress resistance

Antivirulence drugs disarm pathogens rather than kill them, and although they could be effective in theory, antivirulence drugs have never been tested in humans. A new study to be published in the online journal mBio- on Tuesday, October 18 reveals these drugs have the potential to fight infection while avoiding the pitfalls of drug resistance.

11 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

MD Anderson initiates orders of Cesium-131 to help control intermediate risk prostate cancer

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that MD Anderson Cancer Center has initiated orders of Cesium-131 brachytherapy (internal radiation therapy) seeds as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer.

11 Oct 2011

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

Nanostart-holding MagForce AG, a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company's NanoTherm therapy.

11 Oct 2011

Selected prescription drugs contribute to 10% of lower urinary tract symptoms among men

Use of selected prescription medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and diuretics contribute to 10 percent of lower urinary tract symptoms among men according to a Kaiser Permanente study published in the Archives of Internal Medicine.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011